2.2 Acute and Chronic Heart Failure, Cardiomyopathies, and Valvular Heart Disease
Key Takeaways
In decompensated heart failure, assess congestion and perfusion separately. Identify the precipitant and escalate urgently when shock, a mechanical complication or severe hypoxaemia is suspected.
In an acute presentation, NT-proBNP below 300 pg/mL makes heart failure less likely. Consider confounders and investigate persistent clinical suspicion. HSE GP thresholds for non-acute referral have a different purpose.
In acute cardiogenic pulmonary oedema, give oxygen for hypoxaemia, consider early non-invasive ventilation for respiratory distress, treat congestion and consider IV nitrate when blood pressure permits.
ESC 2026 groups symptomatic HF as HFrEF with LVEF below 50% or HFpEF with LVEF at least 50% and corroborating findings. Select treatment using the current guideline and drug-specific indications.
Allow at least 36 hours between an ACE inhibitor and sacubitril/valsartan. Exertional syncope with severe aortic stenosis warrants prompt specialist valve assessment even if ejection fraction is preserved.
Decompensated heart failure at the bedside
Heart failure is a syndrome of symptoms or signs due to cardiac dysfunction. Orthopnoea, exertional breathlessness, fatigue and swelling are common. Acute deterioration may result from ischaemia, rapid arrhythmia, infection, uncontrolled hypertension, medication changes or mechanical valve disease. Assess vital signs, oxygenation, ECG and perfusion promptly, and obtain urgent echocardiography when unstable or when a mechanical complication is suspected.
| Bedside profile | Findings and initial reasoning |
|---|---|
| Congested and perfused | Raised JVP, oedema, orthopnoea or crackles with preserved peripheral perfusion. Treat volume excess and the cause. Consider vasodilation when appropriate for BP and the clinical setting. |
| Congested and hypoperfused | Look for cold extremities, altered mentation, oliguria or raised lactate. Hypoperfusion and organ injury can indicate cardiogenic shock even without a markedly low BP. Get urgent expert support, treat the cause and select vasoactive or mechanical support when indicated. |
| Hypoperfused without obvious congestion | Consider insufficient filling, RV infarction or severe low output. Use examination and bedside imaging to guide treatment. A small assessed fluid challenge may help selected patients with insufficient filling. |
| Perfused without congestion | In a stable patient, address the cause and optimise chronic therapy. |
Raised JVP and a sustained abdominojugular response support high right-sided filling pressure. An S3, pulmonary crackles or dependent oedema can support the diagnosis. No finding alone is diagnostic, and clear lungs do not rule out chronic congestion or isolated right-sided failure. In new dyspnoea consider acute coronary syndrome, pulmonary embolism, infection and obstructive lung disease as alternatives or triggers. ESC 2026 heart failure guideline
Natriuretic peptides and imaging
| Setting or investigation | Interpretation |
|---|---|
| Acute suspected decompensation | ESC 2026 uses NT-proBNP below 300 pg/mL or BNP below 100 pg/mL as acute rule-out thresholds. If clinical suspicion remains, seek specialist assessment and echocardiography despite a low result. |
| Higher acute NT-proBNP | The October 2026 European emergency consensus uses above 450 pg/mL under age 50, above 900 at 50–75 and above 1,800 over 75 as values supporting acute HF. These are probabilistic. Older age, atrial fibrillation, kidney dysfunction, sepsis and pulmonary embolism may raise concentrations. Obesity, flash oedema and right-sided HF may yield lower results. |
| HSE GP suspected non-acute HF | The HSE GP pathway lists NT-proBNP below 400 ng/L as making HF less likely, above 400 for echocardiography and above 2,000 for urgent echocardiography and specialist review. Use the actual referral pathway for borderline values and investigate persistent symptoms. Numerically, ng/L and pg/mL are equivalent. |
| Chest radiograph | Look for vascular redistribution, interstitial markings or Kerley B lines, alveolar oedema and pleural effusions. An enlarged silhouette can support chronic cardiac disease, particularly on a PA film, but a normal film does not exclude HF. |
| Echocardiogram | Assess ventricular size and systolic and diastolic function, filling pressures, valve lesions and regional wall motion. ESC 2026 uses LVEF below 50% for HFrEF in the appropriate symptomatic setting. HFpEF has LVEF at least 50% with clinical and objective evidence supporting HF. Older sources may describe LVEF 41–49% as mildly reduced. |
Sacubitril/valsartan can affect BNP interpretation because neprilysin is involved in BNP breakdown. NT-proBNP is not a direct neprilysin substrate. Interpret either result alongside the clinical trajectory and other causes of variation. ESC 2026 HF guideline · 2026 emergency consensus · HSE GP diagnostics
Acute cardiogenic pulmonary oedema
Assess oxygenation, work of breathing, BP and perfusion together. Sit the patient upright as tolerated, monitor closely and address causes such as ischaemia, severe hypertension, arrhythmia or a valve emergency.
- Respiratory support: Give oxygen for hypoxaemia. ESC uses SpO₂ below 90% or PaO₂ below 60 mmHg as indications. Consider early non-invasive positive pressure ventilation, such as CPAP, for distress with a respiratory rate above 25/min and SpO₂ below 90%. Monitor BP and response. Positive pressure may impair venous return in hypotension or preload-dependent states. Escalate promptly if ventilation fails, airway protection is inadequate or instability persists.
- Decongestion: Use an IV loop diuretic for fluid overload. ESC 2026 gives 40 mg IV furosemide as an example in a diuretic-naive patient and advises considering twice the usual total oral loop dose, in IV equivalent, for a patient already taking a loop. Adjust for renal function, haemodynamics and prior treatment. If clinically suitable, a person taking furosemide 40 mg orally daily may initially receive 80 mg IV. Check early urine output, symptoms, creatinine and electrolytes. ESC gives a two-hour urine sodium of at least 70 mmol/L or urine output at least 100 mL/h in the first six hours as example response measures. Reassess and escalate therapy if congestion persists and response is inadequate.
- Vasodilation: Titrated IV nitrate can be considered when systolic BP is above 110 mmHg, particularly with marked hypertension. Review contraindications and monitor for hypotension. A patient with acute pulmonary congestion may have redistribution rather than a large increase in total body volume.
- Beta-blockers: Avoid starting or increasing a beta-blocker to treat acute unstable decompensation. Review a current prescription according to perfusion, BP, heart rate and conduction. Continue when tolerated, but reduce or withhold when shock or other contraindications require it, and reassess after stabilisation.
Chronic heart failure therapy
For eligible patients with symptomatic HFrEF, the 2026 ESC foundational regimen includes an ACE inhibitor or ARNI (an ARB when appropriate), an evidence-based beta-blocker, a steroidal mineralocorticoid receptor antagonist (MRA) and an SGLT2 inhibitor. For symptomatic HFpEF, ESC recommends an SGLT2 inhibitor and an appropriate MRA when suitable. Use loop diuretics for congestion. Consider BP, kidney function, potassium, volume status and comorbidities. Earlier trials and medicine licences may use different LVEF thresholds.
- ACE inhibitor, ARNI and ARB: Sacubitril/valsartan combines neprilysin inhibition and angiotensin receptor blockade. The Entresto label requires at least 36 hours between stopping an ACE inhibitor and the first ARNI dose, and the same interval before starting an ACE inhibitor after stopping an ARNI. This reduces the risk of angioedema. Stop a prior ARB before starting Entresto, which already contains valsartan. Monitor BP, potassium and kidney function.
- Beta-blocker: Use an evidence-based agent such as bisoprolol, carvedilol or extended-release metoprolol succinate in stable HFrEF. Start low once haemodynamically stable and adjust to tolerance. Monitor rate, pressure and signs of recurrent decompensation.
- MRA: Use a suitable drug and check the specific label. For example, Irish Inspra should not be started with potassium above 5.0 mmol/L and is contraindicated in severe renal impairment. Lower starting frequency applies in moderate renal impairment. Check potassium at baseline, within the first week, at one month and after dose changes according to the product guidance. Finerenone has an EU indication for symptomatic chronic HF with LVEF at least 40%, with separate renal and potassium dosing rules.
- SGLT2 inhibitor: Dapagliflozin and empagliflozin at 10 mg once daily can benefit suitable patients with symptomatic chronic HF, including without diabetes. The Forxiga label advises against starting below GFR 25 mL/min and the Jardiance label below eGFR 20 mL/min/1.73 m². Assess volume status and discuss interruption during serious acute illness or major surgery as indicated.
Arrange early follow-up after a new diagnosis or hospitalisation to check symptoms, tolerance and laboratory results, and optimise therapy. Address the underlying cause and consider rehabilitation and specialist assessment for devices or valve treatment where appropriate. ESC 2026 HF guideline · Entresto · Inspra · Kerendia · Forxiga · Jardiance
Aortic stenosis
Degenerative calcification and bicuspid aortic valve disease are important causes. Exertional breathlessness, angina or syncope can indicate symptomatic severe disease. Look for a slow-rising, low-volume carotid pulse, soft aortic component of S2 and a harsh ejection systolic murmur radiating to the carotids. Murmur intensity alone is unreliable, particularly in low-flow disease.
High-gradient severe AS is supported by peak velocity at least 4.0 m/s and mean gradient at least 40 mmHg, typically with valve area at or below 1.0 cm². Interpret the parameters together. Discordant low-gradient measurements require review of image quality, flow and ventricular function, with specialist use of stress echo or CT valve calcium when appropriate.
Refer symptomatic severe AS promptly to a Heart Valve Centre for intervention assessment. A preserved LVEF does not negate the indication. Asymptomatic patients need specialist risk assessment, including LV dysfunction, exercise symptoms where testing is appropriate and other risk markers. Current ESC/EACTS guidance also supports consideration of earlier intervention in selected asymptomatic patients with severe high-gradient AS and low procedural risk.
For patients aged at least 70 with tricuspid AS, suitable anatomy and feasible transfemoral access, ESC/EACTS 2025 favours TAVI as the primary approach. Surgery remains preferred for low-risk patients younger than 70. Valve morphology, anatomy, life expectancy, need for other surgery, procedural risk and patient preference matter. The Heart Team selects the intervention. ESC/EACTS 2025 valvular guideline
Other valve lesions and myocardial disease
| Lesion | Clinical findings and decisions |
|---|---|
| Aortic regurgitation | Chronic disease can produce a blowing early diastolic murmur, wide pulse pressure and a displaced hyperdynamic apex. Aortic root disease, bicuspid valve and leaflet disease are causes. Acute severe AR from endocarditis or dissection can present with shock or pulmonary oedema without classic chronic signs. Seek urgent expert intervention. For chronic severe AR, use symptoms, LV function and dimensions, and aortic disease to guide surgery. |
| Mitral regurgitation | A pansystolic apical murmur radiating to the axilla is typical of chronic primary MR. Acute severe MR may sound quieter. Primary MR reflects leaflet or apparatus disease, whereas secondary MR may result from ventricular or atrial remodelling. Refer severe primary MR for valve assessment. LVEF at or below 60% or LV end-systolic diameter at least 40 mm indicates LV consequences even without symptoms. Durable repair is preferred when feasible. Secondary MR needs HF treatment and Heart Team evaluation when severe symptoms persist. |
| Mitral stenosis | Rheumatic MS can cause an opening snap and low-pitched diastolic rumble at the apex, with dyspnoea, AF and embolic risk. A valve area at or below 1.5 cm² is clinically significant in rheumatic disease. Interpret gradients in light of heart rate and flow. Percutaneous commissurotomy can suit symptomatic patients with favourable anatomy, no left atrial thrombus and no more than mild MR. Use a vitamin K antagonist for AF with moderate-to-severe MS. |
| Right-sided valve disease | Significant tricuspid regurgitation can cause systemic congestion, prominent systolic jugular waves, hepatic congestion and a lower left sternal systolic murmur that may increase on inspiration. It is often secondary to right-sided or atrial enlargement. Echo evaluates mechanism, RV function and other valve disease. Diuretics can relieve congestion, and timely referral is important before advanced RV or end-organ damage. Pulmonary valve stenosis or regurgitation often has a congenital or post-intervention context and warrants congenital cardiology evaluation when significant. |
Cardiomyopathy: Consider hypertrophic cardiomyopathy when otherwise unexplained LV thickening is seen with exertional symptoms, arrhythmia or a relevant family history. In adults, unexplained maximal wall thickness at least 15 mm supports the diagnosis. Dilated cardiomyopathy combines ventricular dilatation and systolic dysfunction not explained solely by loading conditions or coronary disease. Use ECG, echo and specialist-directed cardiac MRI, and assess family history, arrhythmia risk and whether relatives need screening.
Myocarditis: Suspect it with otherwise unexplained chest pain, arrhythmia or new heart failure, sometimes after an infection. Check ECG, troponin and ventricular function, and evaluate ACS when appropriate. Cardiac MRI can demonstrate inflammation. Shock, significant arrhythmia or advanced conduction block requires urgent specialist care. The specialist team determines whether biopsy is indicated and guides treatment and return to exercise. ESC/EACTS valves · ESC cardiomyopathies · ESC 2025 myocarditis guideline
A 71-year-old woman with chronic ischemic heart failure and a left ventricular ejection fraction of 28% attends the cardiology clinic. She remains symptomatic with breathlessness on climbing one flight of stairs (NYHA Class III) despite taking ramipril 10 mg once daily, bisoprolol 10 mg once daily, and spironolactone 25 mg once daily. Her blood pressure is 122/74 mmHg, heart rate is 68 bpm, eGFR is 52 mL/min/1.73m², and serum potassium is 4.6 mmol/L. The consultant decides to transition her from ramipril to sacubitril/valsartan. Which instruction regarding the transition is mandatory?
Initiate sacubitril/valsartan concurrently with ramipril for 5 days before stopping ramipril
Double the dose of spironolactone to 50 mg daily 48 hours prior to starting sacubitril/valsartan
Stop ramipril and immediately start sacubitril/valsartan at the next scheduled morning dose
Stop ramipril and wait at least 36 hours after the last dose before the first dose of sacubitril/valsartan.
An 82-year-old man presents to the emergency department with acute severe breathlessness and orthopnoea. On examination, he is diaphoretic and sitting bolt upright. Blood pressure is 182/98 mmHg, heart rate is 106 bpm, respiratory rate is 32 breaths/min, and oxygen saturation is 84% on room air. Auscultation reveals diffuse bibasilar crackles extending to the mid-zones bilaterally and an S3 gallop. The jugular venous pressure is elevated 5 cm above the sternal angle. A 12-lead ECG demonstrates sinus tachycardia and left ventricular hypertrophy with strain pattern, but no acute ST-segment elevation. While providing oxygen and assessing for IV diuresis and titratable nitrate, which additional treatment is most appropriate now?
Start monitored non-invasive positive pressure ventilation such as CPAP and reassess oxygenation and haemodynamics promptly.
Initiate an intravenous bisoprolol infusion; administer a 1000 mL intravenous 0.9% normal saline bolus
Initiate oral sacubitril/valsartan; administer an intravenous digoxin bolus
Initiate oral spironolactone 50 mg; perform immediate bilateral therapeutic thoracentesis
A 74-year-old retired farmer presents with two episodes of exertional syncope while walking up a steep incline on his farm. On physical examination, his blood pressure is 106/82 mmHg and his carotid pulses are slow-rising and of low volume (pulsus parvus et tardus). Precordial auscultation reveals a normal apex beat, a soft, single second heart sound, and a harsh crescendo-decrescendo systolic murmur heard loudest at the second right intercostal space, radiating to both carotid arteries. Transthoracic echocardiography confirms an aortic valve area of 0.7 cm², a peak transvalvular velocity of 4.5 m/s, and a mean pressure gradient of 48 mmHg. Left ventricular ejection fraction is 54%. What is the most appropriate management plan?
Reassure the patient and repeat the transthoracic echocardiogram in 12 months as his ejection fraction is preserved
Prescribe oral diltiazem to lower transvalvular shear stress and advise avoidance of strenuous physical activity
Prescribe sublingual glyceryl trinitrate for exertional chest tightness and initiate high-dose bisoprolol
Refer for urgent aortic valve replacement (surgical AVR or transcatheter TAVI)
Sections you finish are checked off in the contents.